BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Mabwell Doses First Patient In United States First In Human Trial Of Novel CDH17 Targeting ADC For Gastrointestinal Cancers

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed...

January 26, 2026 | News

Ellipses Pharma Limited In Licences First In Class B7H3 Targeted ADC From Innolake Biopharm Co. Ltd To Expand Global Oncology Pipeline

Ellipses Pharma Limited (“Ellipses”), a clinical-stage oncology drug development company with a pipeline of innovative programmes, announced th...

January 26, 2026 | News

Japan’s Daiichi Sankyo Strengthens Oncology Commitment With Toronto Headquarters

Investment in Canadian headquarters fuels expansion of Canadian operations, advancing access to innovative cancer medicines Daiichi Sankyo (TSE: 4568)...

January 23, 2026 | News

D3 Bio Secures FDA IND Clearances To Advance KRAS G12D And G12C Clinical Programme

D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, announced that the U.S. Foo...

January 20, 2026 | News

Bio Sourcing And Zerion Pharma Secure Eurostars Funding To Develop Oral Trastuzumab For HER2 Breast Cancer

Bio‑Sourcing and Zerion Pharma A/S announce that their joint project to develop an oral formulation of Trastuzumab, the pioneer monoclonal antibody...

January 16, 2026 | News

Management of Relapsed/Refractory Multiple Myeloma

Doctors and researchers have made huge steps in treating this blood cancer lately. Yet, most people face a time when the cancer returns or stops responding...

January 14, 2026 | News

Pierre Fabre Laboratories And Iktos Launch AI Driven Oncology Drug Discovery Alliance

Pierre Fabre Laboratories and Iktos, a global leader in Artificial Intelligence (AI) and Robotics on drug discovery, announced an integrated drug disc...

January 12, 2026 | News

Johnson And Johnson Amivantamab Combo Delivers 73% Response Rate In First Line Metastatic Colorectal Cancer

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable res...

January 12, 2026 | News

UP Oncolytics Wins $75,000 Illinois Innovation Voucher To Advance Breakthrough Glioblastoma Therapy

UP Oncolytics, a biotech company in Rosalind Franklin University's Helix 51 biomedical incubator, was awarded an Illinois Innovation Voucher gran...

January 09, 2026 | News

Leading the Future of Care: Patient Organizations Driving Health System Transformation

Real Change Starts with Listening Across the Asia Pacific, Middle East, and Africa, healthcare systems are facing mounting pressures with rising rates of ...

January 05, 2026 | Opinion | By Sung Lee, Executive Director, Region Communications and Patient Advocacy, Asia Pacific, Middle East, Africa (APMA), Novartis

Harbour BioMed Partners With Lannacheng To Advance Next Generation Radionuclide Drug Conjugates

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunolo...

January 02, 2026 | News

KORU Medical Submits FDA 510k For FreedomEDGE Use With PHESGO In HER2 Positive Breast Cancer

KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on t...

January 01, 2026 | News

Senhwa Biosciences Advances CX 5461 Into ADC Combination Trial With Enhertu Backed By US NCI

Senhwa Biosciences has announced a significant clinical milestone with its investigational drug Pidnarulex CX 5461 advancing into a Phase 1...

December 30, 2025 | News

Alphamab Oncology Secures IND Acceptance In China For JSKN033 Phase II Cervical Cancer Study

Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcu...

December 30, 2025 | News

Stay Connected